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Development of tools to be used for in vivo bone tissue regeneration focuses on cellular models and differentiation processes.
In searching for all the optimal sources, adipose tissue-derived mesenchymal stem cells (hADSCs or preadipocytes) are able
to differentiate into osteoblasts with analogous characteristics to bone marrow mesenchymal stem cells, producing alkaline
phosphatase (ALP), collagen, osteocalcin, and calcified nodules, mainly composed of hydroxyapatite (HA). The possibility to
influence bone differentiation of stem cells encompasses local and systemic methods, including the use of drugs administered
systemically. Among the latter, strontium ranelate (SR) represents an interesting compound, acting as an uncoupling factor that
stimulates bone formation and inhibits bone resorption. The aim of our study was to evaluate the in vitro effects of a wide range of
strontium (Sr2+) concentrations on proliferation, ALP activity, and mineralization of a novel finite clonal hADSCs cell line, named
PA20-h5. Sr2+ promoted PA20-h5 cell proliferation while inducing the increase of ALP activity and gene expression as well as
HA production during in vitro osteoinduction. These findings indicate a role for Sr2+ in supporting bone regeneration during the
process of skeletal repair in general, and, more specifically, when cell therapies are applied.
1. Introduction
The development of alternative treatments for bone tissue
regeneration, both in bone fractures and skeletal defects due
to trauma, congenital malformations, or tumor excisions, is
a rapidly growing area of investigation. Despite its several
limitations, bone tissue transplantation at this time represents
the treatment of choice for large bone defects [1]. However, in
recent years, new strategies for improving bone regeneration
have been introduced, and several clinical studies have shown
that humanmesenchymal stem cells (hMSCs) have the ability
to accelerate the healing of bone defects due to their potential
to differentiate into osteoblasts [2–6].These cells, either alone
or in combination with biomaterials enriched with osteoin-
ductive factors (i.e., bone morphogenetic proteins (BMPs)),
have been demonstrated to promote the formation of bone
tissue [7]. Their expansion and multipotential proprieties
indicate adult hMSCs as good candidates for regenerative
cell therapy of injured bone tissue [8]. Classically, hMSCs
are isolated from adult bone marrow aspirates, expanded
ex vivo [9], and implanted in vivo on inorganic biocompatible
(ceramic, hyaluronic acid, and synthetic polymers) osteocon-
ductive scaffolds [10, 11].
In addition to bone marrow, adult hMSCs have been
identified in several tissues such as adipose tissue, dental
pulp, skeletal muscle, umbilical cord, and human amni-
otic fluid [12]. Human stem cells from connective tissues
have the capability to differentiate, under appropriate in
vitro conditions, into various mesenchymal lineages such as
adipocytes, chondrocytes, myocytes, hepatocytes, endothe-
lial cells, hematopoietic cells, neuronal cells, and osteoblasts
[13–22]. In particular, human adipose tissue-derived mes-
enchymal stem cells (hADSCs) have been demonstrated to
have the ability to differentiate into functional osteoblasts,
like human bone marrow-derived mesenchymal stem cells
(hBMMSCs), expressing several osteoblastic phenotypes [23,
24]. When compared to hBMMSCs, hADSCs have been
shown to be immunoprivileged [25, 26], with a higher genetic
stability in long-term culture [27–29]. These characteristics,
together with easier access to large bioptic samples [30–32]
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and lower invasiveness of tissue sampling when compared
to hBMMSCs, make hADSCs an ideal source for bone
regeneration [9].
Human ADSCs are capable of secreting a large number
of cytokines and growth factors that support angiogenesis,
tissue remodelling, and antiapoptotic effects such as VEGF,
HGF, Il-6, Il-7, TNF𝛼, M-CSF, and TGF-𝛽1 [33], all impor-
tant in the bone regeneration process [30]. The safety and
efficacy of hADSCs for tissue reconstruction, as well as for
applications in graft-versus-host disease, are currently under
assessment in clinical trials [34–38]. Furthermore, these cells
are under evaluation for potential use in immunosuppression
in various systemic disorders [25, 26, 39, 40] and in soft tissue
replacement [41, 42].
The application of cell therapies in bone tissue engineer-
ing should also consider the possibility to use systemic drugs
capable of modulating bone cell function and proliferation.
Indeed, several effective drugs are currently available for
the treatment of bone metabolism disorders such as amino-
bisphosphonates (BPs) [43–45], selective estrogen receptor
modulators (SERMs) [46, 47], an antireceptor activator
of NFkB ligand (RANKL) monoclonal antibody [48, 49],
parathyroid hormone peptides [50, 51], and SR [52–54].
All these compounds are either purely antiresorptive or
purely anabolic, but SR, an agent with dual effects on bone
remodelling, is able to stimulate bone formation and inhibit
bone resorption [55, 56].
SR is composed of two cations of Sr2+, which represent
the active component, and one anion of ranelate, which
acts as carrier [57]. In bone, the majority of the strontium
ions are absorbed on the surface of hydroxyapatite crystals
and excreted through the kidneys and the faeces, with a
preferential distribution in cancellous newly formed bone
[58, 59]. In animal studies, an increment in osteoid surface
and bone volume and trabecular thickness have been seen
after SR treatment [60].
Several findings support an osteogenic role for Sr2+,
with stimulatory action on osteoprogenitor cell proliferation
and differentiation into mature osteoblasts, by induction of
osteoblastic proteins expression [22, 61, 62]. Studies on rodent
and human primary osteoblast cultures have shown that
Sr2+, like calcium, acts as an agonist on the calcium-sensing
receptor (CaSR), promoting cell replication, differentiation,
and survival [63–66]. Moreover, through osteoblastic cell
stimulation, Sr2+ is able to influence the osteoclastogenesis
and the function of mature osteoclasts [63, 67–69]. In vitro
studies in both primary human osteoblastic cells and murine
rat calvaria cells have shown that Sr2+ induced an increase
in mRNA and protein levels of osteoprotegerin (OPG) with
suppression of RANKL expression, thus favouring downreg-
ulation of osteoblast-induced osteoclastogenesis [64, 70–72].
Altogether, these findings support a role of Sr2+ on oste-
oblastogenesis and bone repair. Indeed, a study on a cal-
varial defect model in rats has shown that Sr2+ enhanced
the osteogenic differentiation of the MSCs, upregulating
extracellular matrix (ECM) gene expression and stimulating
the Wnt/𝛽-catenin pathway [73]. Moreover, Sr2+ promotes
osteogenic differentiation of rat BMMSCs by increasing
the expression of bone morphogenetic protein-7 (BMP-7),
ALP, Cbfa1/RUNX2, bone sialoprotein, and osteocalcin [74,
75]. Furthermore, an in vitro study on mice BMMSCs has
demonstrated that Sr2+ induces osteoblastic differentiation
through induction of prostaglandin E
2
synthesis [76]. Finally,
Sr2+ enhances the calcium deposition process and promotes
bone repair, through enhancing the osteogenic differentiation
of hMSCs [77, 78].
Given the absence of data on the role of Sr2+ on hADSCs
proliferation and osteoinduction, the aim of this study was
to evaluate the in vitro action of Sr2+ on the molecular
mechanisms regulating these processes in a clonal cell line of
hADSCs.
2. Materials and Methods
2.1. Cell Cultures. A hADSCs line, named PA20, was isolated
from small fragments of subcutaneous adipose tissue biopsy
obtained during orthopedic surgery from a female patient
aged 45 years, after signing informed consent in accordance
with a protocol approved by the Institutional Review Board
for human studies. Briefly, the adipose tissue sample was
minced into small pieces (0.2–0.5mm) and digested for 3 h
at 37∘C in Ham’s F12 Coon’s modification medium supple-
mented with 20% fetal bovine serum (FBS) and 3mg/mL
collagenase type I (C-0130, Sigma-Aldrich). The tissue was
thenmechanically dispersed by pipetting and passed through
a sterile 230 𝜇mstainless steel tissue sieve.The undigested tis-
sue trapped in the sieve was discarded, while the infranatant
containing the hADSCs fraction was collected and the cells
were sedimented by centrifugation at 300 g for 5min. The
cells were resuspended and cultured in 100mm tissue culture
plates at 37∘C in humidified atmosphere with 5% CO
2
in
growth medium (GM); thus Ham’s F12 Coon’s modification
medium supplemented with 10% FBS, 100 IU/mL penicillin,
100 𝜇g/mL streptomycin, and 1 ng/mL basic fibroblast growth
factor (bFGF) was composed. The medium was refreshed
twice a week and the cells were used for further subculturing
or cryopreservation upon reaching 5 × 103 cells/cm2.
The human continuous osteoblastic-like cell line SaOS-
2, derived from human osteosarcoma, obtained from the
American Type Cultures Collection (ATCC, Rockville, MD,
USA) was used as positive control. Cells were cultured in GM
and differentiated in OM as PA20-h5 cell line.
2.2. Cell Cloning. PA20 cells at the 3rd passage were used
for cell cloning. Cells in an active phase of growth were
cloned by the dilution plating technique. Cells were detached
with trypsin 1 : 250 0.4mg/mL in Dulbecco’s phosphate
buffered saline (DPBS) without Ca2+, without Mg2+, with
EDTA 0.2mg/mL, and with glucose 1mg/mL, resuspended
in Coon’s medium + 20% FCS. The cell suspension was
diluted to a concentration of 10 cells/mL in the following
cloning medium: Coon’s + 20% FCS supplemented with 25%
conditioned medium prepared from human foetal fibroblast
culture. The cell suspension was maintained in agitation and
0.1mL was rapidly distributed per well of a 96-well, half area
tissue culture plate. Each well was carefully observed and
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the wells containing only one cell were scored. The cloning
culture was incubated at 37∘C in humidified air with 5%CO
2
.
When colonies reached the consistency of 500–600 cells, they
were detached, collected, and first transferred in 24 multiwell
plates and subsequently expanded in 60mm and 100mm
dishes.
2.3. Soft Agar Assay for Neoplastic Transformation. Neoplas-
tic transformed cells form colonies that grow progressively
in soft agar. A 35mm dish was coated with 1% agar prepared
in culture medium maintained liquid at 45∘C. The dish was
immediately cooled. Cells in growth phase were detached,
suspended in medium, diluted to double the required final
concentration, and maintained at 37∘C. 0.68% agar was
prepared inmedium andmaintained at 45∘C. Cell suspension
was mixed with an equal volume of 0.68% agar, distributed
into the agar coated dish to obtain a final concentration of
2.5 × 10
3 cells/dish, and immediately cooled. The cells were
cultured at 37∘C in humidified air with 5% CO
2
for 3-4 weeks
until the formation of colonies and their growth. Colonies
formed per dish were observed and counted in phase contrast
microscopy.
2.4. Cell Line Characterization. The characterization of the
PA20 cell line and the finite clonal cell line, named PA20-
h5, was performed by studying the doubling time, the soft
agar assay, and finally both the adipogenic and osteogenic
potential differentiation as described below.
2.4.1. Adipogenic Differentiation. PA20 cell line and PA20-
h5 finite clonal line were cultured with a specific adi-
pogenic medium (AM): in Ham’s F12 Coon’s modification
medium supplementedwith 10% (FBS), 100 IU/mLpenicillin,
100 𝜇g/mL streptomycin and 1𝜇M dexamethasone, 1 𝜇M
bovine insulin, and 0.5mM isobutylmethylxanthine (IBMX).
The medium was refreshed twice a week. The expression of
the adipogenic phenotype was evaluated on cells cultured in
AM or GM for 35 days by Oil Red O staining.
2.4.2. Osteogenic Differentiation. PA20 cell line and PA20-h5
finite clonal line were plated on tissue culture dishes at a cell
density of 1×104 cells/cm2 in GM and grown to 70–80% con-
fluence. Afterwards, the medium was switched to osteogenic
medium (OM): Ham’s F12 Coon’s modification medium sup-
plemented with 10% FBS, 100 IU/mL penicillin, 100 𝜇g/mL
streptomycin, 10 nM dexamethasone, 0.2mM sodium L-
ascorbyl-2-phosphate, and 10mM 𝛽-glycerol phosphate. The
medium was refreshed twice a week. The expression of the
osteoblastic phenotype was evaluated at 15 and 30 days from
induction by contemporary monitoring ALP activity and
mineralization by cytochemical staining. For ALP staining,
the cells were washed with DPBS (two times), stained with
a specific dye mixture (5mg naphthol-AS-MX phosphate
sodium salt dissolved in 1mL dimethyl sulfoxide), 40mg Fast
Red Violet LB dissolved in 49mL Tris-HCl Buffer 280mM
pH 9.0 for 30min at 37∘C. Then, the cells were washed
with DPBS (two times), fixed in 4% paraformaldehyde
(PFA)/DPBS for 15min, and washed with ultrapure water
(three times). ALP+ cells were stained in red and nuclei
were counterstained in blue with Mayer’s acid hemalum. For
mineralization staining, the cells were washed with DPBS
(two times), fixed in 4% PFA/DPBS for 15min, and washed
with ultrapure water (three times). Calciummineral deposits
were stained for 2min with 2%Alizarin Red S, pH 6.0, rinsed
with water calciummineralized deposits were stained in red-
orange.
2.5. Treatment with Pharmacological Agents. The effects of
treatment with Sr2+ on cell growth and osteogenic dif-
ferentiation of PA20-h5 cells were evaluated at different
concentrations and times from differentiation, depending
on the parameters tested. In our study, we have used SrCl
2
such as source of Sr2+. For the effects on cell growth, a
range of concentrations of Sr2+ from 5 𝜇M to 400𝜇M were
tested, including 120 𝜇M, the average concentration of Sr2+
detectable in the serum of patients receiving the standard
dose of 2 g/day of SR. For the analysis of ALP activity and in
vitro mineralization, the concentrations of Sr2+ used ranged
from 2.5 𝜇M to 400𝜇M.
2.6. Analysis of Cell Proliferation in the Presence of Sr2+.
PA20-h5 cells were seeded in 100mm diameter dishes at a
concentration of 20,000 cells/dish. After 24 hours, GM was
replaced with Coon’s medium added with 1.5% FCS and
maintained in culture for 3 days. At the end, Coon’s medium
was replaced with Coon’s medium with 1.5% FCS, without
osteogenic induction factors, containing several different
concentrations of Sr2+: 5, 50, 100, 200, and 400 𝜇M. The
number of cells was evaluated at 0, 3, 6, 10, 13, and 16 days, the
growth curves were plotted, and the cell population doubling
time was calculated. Each experimental point was performed
in triplicate, and each experiment was repeated three times.
2.7. Analysis of ALP andCalciumMineralizedDeposits Activity
in Presence of Sr2+. The PA20-h5 clonal line was seeded in
24 multiwell plates at a concentration of 20,000 cells/well. At
confluence, the GM was replaced with OM containing the
fluorophore calcein 1 𝜇g/mL and different concentrations of
Sr2+ from 2.5 𝜇M to 400𝜇Mand incubated from 7 to 35 days.
At the end of the incubation, the cells werewashedwithDPBS
(two times), fixed in 4% PFA/DPBS for 15min, washed with
ultrapure water (three times), dried, and preserved at 4∘C
until the assay. Each experimental point was performed in
quadruplicate and each experiment was repeated three times.
2.7.1. ALP Assay. Each well was incubated with 500𝜇L of
4-methylumbelliferyl phosphate in 280mM Tris-HCl Buffer
pH 9.0 for 15min at 37∘C. The reaction was stopped by the
addition of 2mL 0.1M NaOH. ALP activity was measured
with a spectrofluorometer LS55 (PerkinElmer) at 365 nm 𝜆
excitation and 445 nm 𝜆 emission and expressed in 𝜇U/cm2
using a standard curve of 4-methylumbelliferone 50 nM–
10 𝜇M in 280mM Tris-HCl Buffer pH 9.0.
2.7.2. Calcium Mineralized Deposits Assay. Each well was
incubated with 2mL of 50mM NaEDTA for 30min at 37∘C.
The solution was then transferred into the cuvette and
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Table 1: Primers used for the 𝛽-actin gene.
Gene Primer sequence (5󸀠-3󸀠) Amplicon size (bp) 𝑇𝑚 (
∘C)
𝛽-actin FOR
𝛽-actin REV
GACCTGACTGACTACCTCATGAA
CTTCATGATGGAGTTGAAGGTA 303 60
Table 2: Primers used for RT-PCR.
Gene Primer sequences (5󸀠-3󸀠) Amplicon size (bp) 𝑇𝑚 (
∘C)
PPAR-𝛾2 FOR
PPAR-𝛾2 REV
AGGAGCAGAGCAAAGAGG
CCTCGGATATGAGAACCC 219 58
LPL FOR
LPL REV
AGTTGTACTTCCAGTGCGTCTC
TACTTTCACAGTCGGGTT 366 56
bp, base pairs of amplicon size; 𝑇𝑚 (
∘C), melting temperature (∘C).
the fluorescence measured with a spectrofluorometer LS55
(PerkinElmer) at 494 nm 𝜆 excitation and 517 nm 𝜆 emission
and expressed in 𝜇g/cm2 using a standard curve of calcium
mineralized deposits 25 ng/mL–500𝜇g/mL solubilized in
50mM NaEDTA.
2.8. Gene Expression Analysis
2.8.1. Adipogenic Differentiation. The expression of the adi-
pogenic phenotype in the PA20-h5 cell line was evaluated
on cells cultured on PS in AM or GM for 21 days by RT-
PCR analysis of the marker genes peroxisome proliferator-
activated receptor 2 (PPAR𝛾2) and lipoprotein lipase (LPL).
At 21 days from induction cells were detached and sedi-
mented for RNA extraction. Total RNA was extracted using
RNAwiz RNA Isolation Reagent (Ambion, Inc., Austin, TX,
USA), according to the manufacturer’s protocol. The RNA
was treated with DNA-free Kit (Ambion). Complementary
first strand DNA (cDNA) was synthesized from 1 𝜇g of
total RNA using ImProm-II Reverse Transcription System
(Promega,Madison,WI, USA) andOligo dT according to the
manufacturer’s protocol.The RT-PCR reactions of adipocytic
PPAR𝛾2 and LPL genes were performed in triplicate, using
𝛽-actin as control. Reverse transcription products (2–5𝜇L)
were amplified in Bio-Rad iCycler system thermocycler
(Bio-Rad Laboratories S.r.l., Segrate, Milan, Italy) using a
25 𝜇L reaction mixture containing 1 𝜇m of each primer and
puRe Taq Ready-To-Go PCR Beads (Amersham Biosciences
Corp., Piscataway, NJ, USA) with a standard thermal profile.
Sequence, 𝑇
𝑚
, and expected fragment size for each pair of
primers are shown in Tables 1 and 2. The identity of each
PCR product was confirmed by agarose gel electrophoresis
and directDNA sequencing using anABI-Prism 3100Genetic
Analyzer (Applied Biosystem, Foster City, CA, USA).
2.8.2. Osteogenic Differentiation. Gene expression analysis in
the PA20-h5 cell line before and after 21 days in GM or
OM was performed in the presence of 100 𝜇M Sr2+, a
concentration known to be active on both cell proliferation
and ALP enzymatic activity. The genes included in the
analysis were ALP (known to be involved in the initial
phases of the osteogenic differentiation), RUNX2 (known as
a precocious transcriptional factor during the osteoblastic
differentiation), and DKK1 (known to be an antagonist of
osteoblastic differentiation).
Total RNAwas extracted from frozen PA20-h5 cell pellets
withQiazol reagent (Qiagen) according to themanufacturer’s
instructions. Concentration, purity, and integrity of the total
RNA were checked with an ND-1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) and also
with an electrophoresis run on a 0.8% agarose gel. Onemicro-
gram of total RNA was reverse-transcribed using QuantiTect
Reverse Transcription Kit (Qiagen) according to manual
instructions. To verify the successful reverse transcription,
qualitative PCR was performed using 1 𝜇L cDNA as template
and 10 𝜇M of each primer (forward and reverse) (Table 1)
of the gene housekeeping 𝛽-actin. The genetic expression
analysis by quantitative real time PCR (qRT-PCR) for ALP,
runt-related transcription factor-2 (RUNX2), DKK1, and
40S ribosomal protein S18 (RPS18) was performed using
StratageneMx3000-P Detection System (Stratagene, La Jolla,
CA, USA). Reactions were carried out using a TaqMan 5󸀠-
exonuclease assay, following the thermic profile according to
manual instructions (Kapa probe fast qPCRKit, Kapa Biosys-
tems). The primers and internal labelled oligonucleotides
TaqMan probes for each cDNA, described in Table 2, were
designed by IDT integrated DNA technologies. The cDNA
samples used for the construction of standard curves for
quantitative analysis were subjected to PCR amplification
for each gene (primer sequences are indicated in Table 3),
and PCR products were analyzed by 0.8% agarose gel elec-
trophoresis visualized by ethidium-bromide staining and in
the presence of marker VIII (Roche) performed by agarose
gel elution band with KitMillipore.The standard curves were
generated by assessing serial cDNAdilutions (10-fold dilution
for 8 logarithms) and plotting fluorescence versus the Ct
(threshold cycle) based on dRn (baseline corrected, reference
dye-normalized fluorescence). All points for standard curves
and unknown samples were performed in triplicate. Negative
control tubes with water were included in each real-time
PCR run to detect any carry-over contamination. Target gene
expression was normalized to RPS18.
2.9. Statistical Analysis. For proliferation analysis, statistical
processing was performed during the “log phase” of the
growth curves using (a) the linearity test by Student’s 𝑡-test
and the 𝑅2 coefficient of determination for each regression
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Table 3: Primers and TaqMan probes used for qRT-PCR.
Gene Primer sequences (5󸀠-3󸀠) and TaqMan probes Amplicon size (bp) 𝑇𝑚 (
∘C)
RPS18 FOR
RPS18 REV
probe
TCTTCCACAGGAGGCCTAC
GATGGCAAAGGCTATTTTCCG
F/TTCAGGGAT/ZEN/CACTAGAGACATGGCTGC/Q
132 60
ALP195 FOR
ALP195 REV
probe
CCCGTGGCAACTCTATCTTTG
CATACAGGATGGCAGTGAAGG
F/TTCTTGTCT/ZEN/GTGTCACTCAGCATGGG/Q
78 60
DKK1 FOR
DKK1 REV
probe
TGATCATAGCACCTTGGATGG
ACACAATCCTGAGGCACAG
F/CTGATGACC/ZEN/GGAGACAAACAGAACCTT/Q
121 60
RUNX2 FOR
RUNX2 REV
probe
AGGGACTATGGCATCAAACAG
CTTCACGTCGCTCATTTTGC
F/TCTTTTGGA/ZEN/TCCGAGCACCAGCC/Q
135 60
TaqMan probes with F as reporter fluorochrome (6-carboxyfluorescein [6-FAM]) and Q as quencher.
Fluorochrome (Iowa Black FQ); bp, base paris of amplicon size; 𝑇𝑚, melting temperature (
∘C).
0 days
(a)
35 days
(b)
Figure 1: Observation in brightfield microscopy of PA20-h5 line after 0 days (a) and 35 (b) days of adipogenic induction. Cytochemical
staining with Oil Red O; intracellular deposits of lipids stained in red; nuclei counterstained in blue-violet with hematoxylin (20x objective).
and (b) the parallelism test by Student’s 𝑡-test to compare
growth curves in the presence of the different Sr2+ con-
centrations with the growth curve of the control. For ALP
and calcium mineralized deposits assays the experiments
were carried out in quadruplicate and each experiment
was repeated three times. Gene expression analysis was
performed in triplicate. All data were expressed as means ±
S.D. Statistical differences among mean values were analyzed
using Student’s 𝑡-test.
3. Results
3.1. Cell Line Characterization. The PA20 cell line showed a
doubling time of 67 days, while the PA20-h5 finite clonal cell
line showed a doubling time of 56 days.The PA20-h5 line did
not show growth in soft agar after 4 weeks in culture.
3.2. Adipogenic Differentiation. Adipogenic differentiation
was not observed in the PA20-h5 line at time 0 (days), while
after 35 days of adipogenic induction some cells showed
intracellular vacuoles containing drops of lipids of variable
shape and size (Figure 1). Similar results were observed in the
primary PA20 cell line (data not shown).
Adipogenic differentiation was confirmed by RT-PCR of
adipocyte-specific LPL and PPAR𝛾2 genes. In the absence
of adipogenic induction, qualitative RT-PCR showed lack
of expression for PPAR𝛾2 gene and a minuscule expression
for LPL gene in the PA20-h5 line, while after 21 days
from adipogenic induction, qualitative RT-PCR revealed
a bright band on agarose gel for both genes (data not
shown).
Adipogenic differentiation was not effected on SaOS-2
cell line, insofar as this line is already irrevocably directed in
osteogenic sense.
3.3. Osteogenic Differentiation
3.3.1. ALP Activity. PA20-h5 line did not show ALP activity
at time 0 (days), while culture in the OM up to 35 days
induced an increase in the number of cells positive to ALP
that was time-dependent up to a maximum of approximately
40% of the cell population at 35 days (Figures 2(a), 2(b), and
2(c)). SaOS-2 cell line at only time 0 presents already 100%
positivity, as expected for an osteoblast-like cell line, where
all cells are already directed in osteogenic sense (data not
shown).
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ALP
0 days
14 days
35 days
HA
(a)
(b)
(f)(c)
(e)
(d)
Figure 2: Observation in light microscopy of osteogenic differentiation of the PA20-h5 line at 0 days ((a), (d)), 14 days ((b), (e)), and 35
days of induction ((c), (f)). Cytochemical staining for ALP ((a), (b), and (c)): positive cells stained in red and nuclei counterstained in blue
(observation in brightfield microscopy, 20x objective). Cytochemical staining for calcium mineralized deposits ((d), (e), and (f)): deposits
stained in red-orange (observation in phase contrast microscopy, 20x objective).
3.3.2. Calcium Mineralized Deposits. Results obtained
showed a production of calcium mineralized deposits in the
PA20-h5 line cultured with OM for 35 days. The number and
size of the mineralized nodules were time-dependent. After
35 days, cell death and degeneration were observed near
large mineralized deposits (Figures 2(d), 2(e), and 2(f)).
3.4. Analysis of Cell Proliferation in the Presence of Sr2+.
Statistical processing performed during the “log phase” of
the growth curves has shown the goodness of the linearity of
the individual regressions (𝑃 < 0.001), with 𝑅2 coefficient
of determination, which always resulted greater than 0.80.
The comparison between the linear regressions of the growth
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y = 4x + 4.27750.005
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2x + 4.2839y = 0.014
R2 = 0.8432
R2 = 0.8368
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doubling time:
Control: 56d
Sr 5𝜇M: 60d
Sr 50𝜇M: 68d
Sr 100𝜇M: 21d
Sr 200𝜇M: 86d
Sr 400𝜇M: 38d
5x + 4.2782y = 0.003
+ 4.2717y = 0.008x
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Figure 3: Graphical representation in linear regression of the
kinetics of growth for PA20-h5 line cultured in Coon’s medium +
FCS 1.5% in the presence of Sr2+ concentrations from 0 to 400𝜇M.
The equation and the 𝑅2 value are reported for each straight line.
Experiments are carried out in triplicate and are representative of
three different experiments.
curves in presence of different Sr2+ concentrations and the
control have shown significant differences (𝑃 < 0.001) for
100 𝜇MSr2+ versus control with a respective doubling time of
21 days and 56 days. At lower and higher concentrations Sr2+
had no significative effects (Figure 3).
On SaOS-2 cell line was observed an analogous response
with a significant increase versus control of the proliferative
activity in the presence of 100 𝜇M Sr2+ (data not shown).
3.5. Quantitative Analysis of ALP Enzymatic Activity. At
100 𝜇M–400 𝜇Mconcentrations, Sr2+ significantly stimulated
ALP production in the PA20-h5 cells, from 14 to 35 days, with
maximal response being observed at 21 days with 400𝜇M
Sr2+ (150% versus control) and a decrease at longer times
of observation (Figure 4(a)). Lower Sr2+ concentrations were
inactive.
3.6. Quantitative Analysis of the Formation of Calcium Min-
eralized Deposits. A significant increase of HA production
was observed compared to control from 14 to 35 days only
at low Sr2+ doses (2.5 𝜇M–50 𝜇M). The maximal response
was observed at 28 days for 5𝜇M Sr2+ with an increase of
480% versus control. At higher concentrations, Sr2+ did not
significantly affect HA production (Figure 4(b)).
Similarly, on SaOS-2 cell line the 5𝜇MSr2+ concentration
seems to be the most effective between concentrations tested
at 28 days with an increase from 14 to 35 days compared to
control (data not shown).
3.7. Gene Expression Analysis of ALP, RUNX2, and DKK1.
Analysis of data showed the absence of significant variations
of ALP, RUNX2, and DKK1 gene expression in cells cultured
in GM containing 100 𝜇M Sr2+ compared to those cultivated
only in GM (Figures 5(a), 5(c), and 5(e)). However, ALP
and RUNX2 expression significantly increased in a time-
dependent manner for both cells cultivated in OM and
those cultivated in OM containing 100 𝜇M Sr2+, reaching a
maximum for ALP at 12 days and for RUNX2 at 18 days and
both decreasing with time (Figures 5(b) and 5(d)). Significant
increases of ALP expression were observed in cells cultured
in OM containing 100 𝜇M Sr2+ at 6 days, both versus OM at
6 days (𝑃 < 0.005) and versus OM containing 100 𝜇M Sr2+
at 3 days (𝑃 < 0.001). Furthermore, significant increases of
ALP expression were also observed in cells cultured in OM
and in OM containing 100 𝜇M Sr2+ at 12 days, respectively,
versus OM and OM containing 100 𝜇M Sr2+ at 3 days (𝑃 <
0.01) (Figure 5(b)). No variation ofDKK1 expression has been
observed for cells cultivated in OM containing 100𝜇M Sr2+
compared to those cultivated in OM (Figure 5(f)).
4. Discussion
Strontium ranelate has been shown in clinical trials to protect
against bone loss and to reduce the risk of vertebral and hip
fractures in postmenopausal women with osteoporosis [53,
54].
SR has a dual mode of action that differentiates it
from other available treatments for osteoporosis. Indeed, it
induces opposite effects on osteoclast and osteoblast in vitro
cultures (i.e., enhances preosteoblast replication and collagen
synthesis and inhibits osteoclast differentiation and resorbing
activity by stimulating osteoclast apoptosis) [56]. These in
vitro effects result in vivo in increased bone architecture
and bone strength in studies on animal models [60–62, 67,
68]. In particular, in in vivo studies, on rat model treated
with biomaterial Sr-enriched, the F18-fluoride PET analysis
showed that the Sr released by biomaterial is incorporated in
the mineralized matrix, promoting the bone healing [79].
In this paper, we describe the effect of Sr2+ on a novel
adipose tissue-derived clonal human cell line, named PA20-
h5. The PA20-h5 cell line shows a staminality feature, as
confirmed by its differentiative capacity in both osteogenic
and adipogenic lineages. This finding has important implica-
tions, as a human clonal cell line capable of expressing this
phenotype has not been described before.
A wide range of Sr2+ concentrations was tested in PA20-
h5 cell proliferation, ALP activity, and in vitromineralization,
showing the Sr2+ capability to promote both proliferation and
osteoblastic differentiation.
The proliferative effects were seen at 100 𝜇M Sr2+ con-
centration, very close to the circulating doses of Sr2+ in
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Figure 4: Quantitative analyses of ALP enzymatic activity (a) and calcium mineralized deposits (b) in PA20-h5 cultured in OM in the
presence of scalar concentrations of strontium from 4 to 35 days. Experiments are carried out in triplicate and are representative of three
different experiments.
patients treated with the standard dose 2 g/day of SR [53, 56].
In vitro studies on rat calvarial cultures showed that SR at
concentrations 0.01–1mM and 5–10mM enhanced the cell
replication [62, 65].
In vitro osteodifferentiation of PA20-h5 cells monitored
by ALP production was observed at 400 𝜇M Sr2+ concentra-
tion, supporting a role for Sr2+ in the early induction of bone
differentiation. Indeed, a study on the mouse osteoblastic
MC3T3-E1 cell line treated with 1mM Sr2+ showed a sig-
nificant increase of ALP activity at 4 and 14 days of culture
compared with control [61].
At lower concentrations (2.5 to 50 𝜇M), Sr2+ stimulated
HA production in the PA20-h5 cell line, with an opposite
effect at higher concentrations (200𝜇M and 400 𝜇M). This
biphasic action indicates that low Sr2+ concentrations are
capable of influencing the in vitro mineralization process.
Altogether, the differential dose-dependent effects of Sr2+
on various steps of PA20-h5 osteoblastogenesis evidenced
the complexity of the interaction of the cation bioeffects
on the bone regeneration process. In fact, the higher doses
(200𝜇M and 400𝜇M) of Sr2+ in the PA20-h5 seem to
inhibit the formation of HA deposits presupposing alter-
ations of the physicochemical properties in the struc-
ture of hydroxyapatite crystal up to impede its formation
[80, 81].
The increase in ALP production was confirmed by gene
expression results in which 100 𝜇M Sr2+ induced an increase
in ALP gene expression in PA20-h5 osteoinduced cells, with
no effect on RUNX2 and DKK1 gene expression. Based on
these results, Sr2+ seems to act early on the in vitro osteogenic
induction of the PA20-h5 cell line.These observations do not
seem to confirm previous findings in other cellular models.
Indeed, an in vitro study on rat BMMSCs has shown that SR at
concentrations of 0,1, and 1mM Sr2+ promotes the osteoblas-
tic differentiation both by increase of ALP expression and by
mRNA levels of RUNX2, bone sialoprotein, and osteocalcin,
while it significantly inhibits proliferation [75]. Another in
vitro study showed induction of early expression of RUNX2 at
day 4 by Sr2+ in hMSCs [78]. In addition, it was demonstrated
that 4mM Sr2+ increased mRNA expression of RUNX2 and
osteocalcin (OCN) in hMSCs in vitro [82].
Finally, in primary osteoblasts derived from mouse cal-
varia, 0.1–1mM SR concentrations promoted bone nodule
formation, increasing the differentiation from early progeni-
tor cells tomature osteoblasts, as reflected also by the increase
of the expression of osteoblastic markers such as ALP, bone
sialoprotein (BSP), andOCN [66]. In another in vitro study, it
was instead seen that, in U-33 preosteoblastic cells, 0.1–1mM
Sr2+ concentrations significantly enhanced the expression of
RUNX2 and OCN genes, but not BSP, while in more mature
osteoblastic OB-6 cells Sr2+ induced only minimal effects on
RUNX2 expression, but presented a positive effect onBPS and
OCN expression [66].
The differences in the results obtained encompass both
sensitivity to Sr2+ challenge and qualitative responses. The
reason for such variability could be explained by the diverse
cellular models used up to now, which include rodent versus
human cell cultures and clonal versus mixed cellular models.
It seems, therefore, reasonable to address future research in
this area using human models and continuous cell lines. This
will make it possible to avoid heterogeneity in the response to
Sr2+.
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Figure 5: Analysis of gene expression ofALP ((a), (b)), RUNX ((c), (d)), andDKK1 ((e), (f)) in PA20-h5 from 3 to 21 days. Culture in medium
GMandGMcontaining 100𝜇MSr2+ ((a), (c) and (e)). Culture inmediumOMandOMcontaining 100 𝜇MSr2+ ((b), (d), and (f)). Experiments
are carried out in triplicate and are representative of three different experiments.
5. Conclusions
Multiple molecular and biological mechanisms are involved
in cell proliferation and osteogenic differentiation in vitro and
in vivo. The present study showed how different concentra-
tions of Sr2+ act on hADSCs depending on the biological
phenomenon analyzed. On the basis of our results, in vitro
Sr2+ ion treatment of hADSCs enhances cell proliferation and
osteogenic differentiation through expression of early and
late osteoblastic biomarkers such as ALP and HA, respec-
tively. This effect is dose-dependent, with a positive effect
at circulating pharmacological Sr2+ doses. These findings
clearly support the use of SR in in vitro induction of bone
regeneration. Future studies will try to answer fundamental
10 Stem Cells International
questions regarding the use of SR treatment in patients
undergoing cell therapy and administration.
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